Literature DB >> 17085311

Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning.

Frédéric Baron1, Barry Storer, Michael B Maris, Jan Storek, Fanny Piette, Monja Metcalf, Kristen White, Brenda M Sandmaier, David G Maloney, Rainer Storb, Michael Boeckh.   

Abstract

The risk of cytomegalovirus (CMV) infection is higher after HLA-matched unrelated donor (URD) than after HLA-matched related donor (MRD) nonmyeloablative hematopoietic cell transplantation (HCT). We therefore investigated factors affecting immune recovery in 94 patients given HCT from MRDs (n = 51) and URDs (n = 43) after 2-Gy total body irradiation with or without fludarabine and postgrafting immunosuppression with mycophenolate mofetil and cyclosporine. CD4 T cells counts remained below normal values during the first year after HCT in both patient groups. This included abnormally low counts each of naive CD4 T cells and memory CD4 T cells. Conversely, CD8 T cell counts reached the 10th percentile of normal 6 months after HCT in MRD and URD recipients. On day 30 after HCT, URD recipients had lower counts of B cells (P = .02), naive CD4 T cells (P = .04), memory CD4 T cells (P = .005), memory CD8 T cells (P = .005), and CMV-specific T helper cells (P = .007) than had MRD recipients. This delay in CMV-specific immune reconstitution translated into increased frequency of CMV antigenemia among URD recipients during the first 100 days after HCT. Older donor age was associated with low counts of naive CD4 T cells on days 180-365 after HCT (P = .003). Further, low numbers of T cells and CD34(+) cells in the graft and development of acute graft-versus-host disease were associated with impaired immune recovery of naive CD4 T cells and B cells. In summary, immunologic recovery was poor the first year after nonmyeloablative conditioning and was delayed among URD recipients in comparison with MRD recipients. Other factors significantly associated with delayed immune recovery were advanced donor age, low numbers of CD34 and T cells in the graft, and development of graft-versus-host disease.

Entities:  

Mesh:

Year:  2006        PMID: 17085311     DOI: 10.1016/j.bbmt.2006.07.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  24 in total

1.  Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Haesook T Kim; Julie Aldridge; Deborah Liney; Grace Kao; Philippe Armand; John Koreth; Corey Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Edwin P Alyea
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-27       Impact factor: 5.742

2.  Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort.

Authors:  Z Gul; E Van Meter; M Abidi; I Ditah; M Abdul-Hussein; A Deol; L Ayash; L G Lum; E K Waller; V Ratanatharathorn; J Uberti; Z Al-Kadhimi
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

Review 3.  The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment.

Authors:  Enrico Velardi; Emmanuel Clave; Franco Locatelli; Antoine Toubert; Lucas C M Arruda; Francesca Benini
Journal:  Semin Immunopathol       Date:  2021-01-08       Impact factor: 9.623

4.  Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation.

Authors:  Stéphane Buhler; Florence Bettens; Carole Dantin; Sylvie Ferrari-Lacraz; Marc Ansari; Anne-Claire Mamez; Stavroula Masouridi-Levrat; Yves Chalandon; Jean Villard
Journal:  Leukemia       Date:  2019-11-26       Impact factor: 11.528

5.  C-reactive protein levels before reduced-intensity conditioning predict outcome after allogeneic stem cell transplantation.

Authors:  Mats Remberger; Jonas Mattsson
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

6.  Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.

Authors:  Hirohisa Nakamae; Barry E Storer; Rainer Storb; Jan Storek; Thomas R Chauncey; Michael A Pulsipher; Finn B Petersen; James C Wade; Michael B Maris; Benedetto Bruno; Jens Panse; Effie Petersdorf; Ann Woolfrey; David G Maloney; Brenda M Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-11-10       Impact factor: 5.742

7.  Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.

Authors:  Hirohisa Nakamae; Katharine A Kirby; Brenda M Sandmaier; Lalita Norasetthada; David G Maloney; Michael B Maris; Chris Davis; Lawrence Corey; Rainer Storb; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-04-16       Impact factor: 5.742

8.  Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies.

Authors:  Sung-Won Kim; Keitaro Matsuo; Takahiro Fukuda; Masamichi Hara; Kosei Matsue; Shuichi Taniguchi; Tetsuya Eto; Mitsune Tanimoto; Atsushi Wake; Kazuo Hatanaka; Shinji Nakao; Yoji Ishida; Mine Harada; Atae Utsunomiya; Masahiro Imamura; Yoshinobu Kanda; Kazutaka Sunami; Fumio Kawano; Yoichi Takaue; Takanori Teshima
Journal:  Int J Hematol       Date:  2008-09-17       Impact factor: 2.490

Review 9.  Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

Authors:  S Abdul Wahid Fadilah; Md Pazil Aqilah
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

10.  Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation.

Authors:  Joshua T Schiffer; Kate Kirby; Brenda Sandmaier; Rainer Storb; Lawrence Corey; Michael Boeckh
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.